Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesGemcitabine, vinorelbine, and cisplatin in the treatment of advanced non small cell lung cancer
American Journal of Clinical Oncology, 06/08/09
Hasturk S et al. – Phase II trial reports that the combination of gemcitabine-cisplatin-vinorelbine (GCV) with lower doses of cisplatin and gemcitabine was effective and active in advanced nonsmall cell lung cancer (NSCLC). The overall response rate, 1-year survival and median survival time were similar to higher doses; toxicities were more acceptable and manageable.
Methods- Aim was to investigate if combination of GCV with lower than usual but acceptable doses of G and C can obtain higher response rate than doublet but less toxicity than triplet combinations
- Stage IIIB and IV chemotherapy naive NSCLC pts with measurable disease and performance status of 0 to 2 were included
- Gemcitabine and vinorelbine at the doses of 900 mg/m2 and 25 mg/m2, respectively were administered on d 1 and 8, and cisplatin at a dose of 50 mg/m2 on d1/ 21 days
- 3/39 (7.7%) pts included were complete responders
- ORR was 56.4%, MTP was 6 mo, median OS time was 12 mo, and 1-yr survival rate was 49.6%
- Grade II to III neutropenia and thrombocytopenia occurred in 24% and 30% of the pts, respectively
- Febrile neutropenia was observed in 13.5% pts, and only these pts received G-CSF
- Platelet and erythrocyte transfusions were required in 12 (32.4%) pts
- No toxic or early death was observed
Related Articles
Lung cancer: a biologically different disease in women?
Women's Health, 10/30/09
Relevance Score: 73%
Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09
Relevance Score: 72%
Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15q24-25.1
Cancer Research, 10/06/09
Relevance Score: 71%
Noninvasive detection of lung cancer by analysis of exhaled breath
BMC Cancer, 10/09/09
Relevance Score: 70%
African American lung cancer patients may have different response to new cancer-fighting drugs
EurekAlert, 10/08/09
Relevance Score: 70%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Sedation during Flexible Bronchoscopy in Patients with Pre-Existing Respiratory Failure: Midazolam versus Midazolam plus Alfentanil
Respiration, 12/18/09
Taurolidine in the prevention and therapy of lung metastases
European Journal of Cardio-Thoracic Surgery, 12/18/09
Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil
Rheumatology, 12/18/09
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Pain in patients with lung cancer: Pathophysiology and treatment
Lung Cancer, 12/18/09
Taurolidine in the prevention and therapy of lung metastases
European Journal of Cardio-Thoracic Surgery, 12/18/09
A small-cell lung cancer genome with complex signatures of tobacco exposure
Nature, 12/18/09
Sponsor
Article Search
Sponsor
Sponsor